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Selling ART: An Empirical Assessment of Advertising on
Fertility Clinics’ Websites
JIM HAWKINS*
Scholarship on assisted reproductive technologies (ART) has emphasized the
commercial nature of the interaction between fertility patients and their physicians,
but little attention has been paid to precisely how clinics persuade patients to
choose their clinics over their competitors’. This Article offers evidence about how
clinics sell ART based on clinics’ advertising on their websites. To assess clinics’
marketing efforts, I coded advertising information on 372 fertility clinics’ websites.
The results from the study confirm some suspicions of prior ART scholarship while
contradicting others. For instance, in line with scholars who are concerned that
racial minorities face barriers to accessing ART, I found that 97.28% of the
websites that contain pictures of babies have pictures of white babies, and 62.93%
have pictures of only white babies. Similarly, in agreement with prior work that
challenges the effectiveness of self-regulation, I found low levels of compliance
with industry-sponsored advertising regulations. Contrary to the assumption held
almost universally in the literature on ART, however, I found that clinics do not
prioritize advertising their success rates. Clinics’ websites are more likely to
emphasize several other attributes of care instead of their success rates. In light of
the new data uncovered by this study, I conclude by offering new regulatory
directions for policymakers to consider as they try to keep up with changes in the
fertility business.
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INTRODUCTION
As many people have pointed out, the practice of assisted reproductive
technologies (ART) is big business.1 The fertility industry generates in excess of $4
billion in gross revenues each year,2 and to generate that revenue, fertility clinics
actively market their services in an attempt to gain market share.3 Many people pay
for ART out of pocket, and these services are expensive, such as in vitro
fertilization (IVF), which costs an average of approximately $12,317.4 Clinics have
significant incentives to attract business.
This Article offers an empirical assessment of the advertising found on fertility
clinics’ websites. Websites are an important source of information about fertility
clinics for patients considering ART. As far back as 2000, a study found that “a
considerable proportion of patients from all socioeconomic levels is currently using
the WWW with regard to their fertility problems.”5 In 2010, 77% of people in
North America were Internet users.6 Online advertising has been an important
factor in helping some countries become destinations for Americans seeking ART.7

1. E.g., DEBORA L. SPAR, THE BABY BUSINESS: HOW MONEY, SCIENCE, AND POLITICS
DRIVE THE COMMERCE OF CONCEPTION (2006).
2. THE PRESIDENT’S COUNCIL ON BIOETHICS, REPRODUCTION & RESPONSIBILITY: THE
REGULATION OF NEW BIOTECHNOLOGIES 153 (2004), available at http://www11.georgetown.edu/
research/nrcbl/pcbe/reports/reproductionandresponsibility/index.html (“Assisted reproduction is
a growing economic enterprise, with gross revenues of $4 billion per year . . . .”).
3. See Kimberly D. Krawiec, Altruism and Intermediation in the Market for Babies, 66
WASH. & LEE L. REV. 203, 213–14 (2009) (“[P]rofits are undeniably a—if not the—
motivating factor in the industry as well. Although many fertility centers are affiliated with
nonprofit hospitals or academic institutions, the fertility center itself is often a professionally
managed, for-profit, private corporation. Those fertility centers not affiliated with academic
institutions are even more openly profit-centered and, like suppliers in any competitive
industry, they engage in elaborate marketing efforts to attract customers. These efforts
include hiring high-priced marketing consultants; advertising on billboards, the radio,
newspapers, and magazines; and assiduously courting physician referrals by ‘wining and
dining’ doctors and hosting dinners and parties at medical meetings.” (emphasis in original)
(footnote omitted)).
4. See infra Part II.D.1.
5. Ariel Weissman, Lynda Gotlieb, Susan Ward, Ellen Greenblatt & Robert F. Casper,
Use of the Internet by Infertile Couples, 73 FERTILITY & STERILITY 1179, 1182 (2000).
6. Kenan Omurtag, Patricia T. Jimenez, Valerie Ratts, Randall Odem & Amber R.
Cooper, The ART of Social Networking: How SART Member Clinics Are Connecting with
Patients Online, 97 FERTILITY & STERILITY 88, 88 (2012).
7. J. Brad Reich & Dawn Swink, You Can’t Put the Genie Back in the Bottle: Potential
Rights and Obligations of Egg Donors in the Cybperprocreation Era, 20 ALB. L.J. SCI. &
TECH. 1, 21–22 (2010) (“An estimated 150,000 medical tourists visited India in 2005 and
that number increased to 450,000 by 2008. Perhaps more telling is that India’s RT
[reproductive technology] segment of medical tourism was approximately $ 450 million per
year in 2006, but projected to grow to six billion dollars by 2008. A significant portion of
this growth is attributable to the Internet and, specifically, to user-friendly websites and
effective, although not necessarily reliable, online advertising.” (footnotes omitted)); Ruby
L. Lee, Note, New Trends in Global Outsourcing of Commercial Surrogacy: A Call for
Regulation, 20 HASTINGS WOMEN’S L.J. 275, 276–77, 284 (2009) (“Surrogacy agencies in
Russia and Slovenia also seek to tap into the market of outsourcing commercial surrogacy by
advertising on the Internet and highlighting the more favorable treatment towards surrogacy
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Fertility websites differ significantly in their style and content, but most have
Home pages with vibrant colors, large pictures of happy babies and doctors, and
information about the clinic.8 More extensive information about the clinic can often
be found on an About page that offers details about the physicians’ backgrounds,
the clinic’s location, and the clinic’s laboratory.9 In addition to a link to an About
page, the Home pages usually have links to a large number of other pages that
contain information about becoming a patient, the types of fertility treatments that
the clinic offers, financing treatments, and other patient education resources.
To provide an in-depth analysis of the content of clinics’ websites, several
research assistants and I looked at every fertility clinic in the United States that is a
member of the Society for Assisted Reproductive Technology (SART), a
professional organization that represents the vast majority of fertility of clinics in
the United States.10 We coded the content of these websites, recording sixty
different points of data for each website. Part II of the Article provides details about
the methodology we followed.
The study has three goals. First, it offers information about what features of
clinics are advertised most frequently. How often clinics present information on
specific topics provides insight into what the clinics think patients value in their
fertility treatment provider. It also reveals potential for subtle misrepresentations by
showing how clinics frame their services. Part III presents findings on this topic.
The most surprising finding from this part of the study was that success rates,
which have received the most academic and regulatory attention, were not the most
common attribute that clinics advertised. Instead, several other parts of the fertility
transaction received greater emphasis. Also, notably, a large number of clinics used
advertising strategies that relied on emotional responses instead of intellectual
responses to information. A high percentage of clinics post pictures of babies on
their Home page, and a significant number use words like “dream” and “miracle.”
In describing the information on how clinics market their services on their
websites in Part III, I approach the fertility business as a market in which patients
make choices as consumers. Thus, one aim of the Article is to understand how law
can help patients as consumers make the best decisions to maximize their welfare.
While it may be difficult to classify people seeking fertility treatments as patients
or consumers because they operate as both, the consumer element of the interaction
between clinics and patients is important because patients are free to pick their
treatment provider.11 To the extent that the law can help those choices best reflect
consumers’ preferences, I argue it should.
The second goal of the study is to understand barriers to access to ART faced by
racial minorities. The content of clinics’ websites offers insight both into how

that their countries provide—vis a vis little or no regulation of commercial surrogacy.”).
8. E.g., Welcome to Brigham and Women’s Hospital: Center for Infertility and Reproductive
Surgery, BRIGHAM AND WOMEN’S HOSPITAL, http://infertility.brighamandwomens.org/index.php.
9. E.g., About Our NY Fertility Clinic, NEW YORK FERTILITY CLINIC,
http://www.fertilitynewyork.com/fertility-specialist.php.
10. Society for Assisted Reproductive Technology, About Us: What Is SART?,
SART.COM, http://www.sart.org/detail.aspx?id=1864.
11. See Naomi Cahn, The New Kinship, 100 GEO. L.J. 367, 372 (2012) (“ART is
focused on patients, and on finding treatments for them in a medicalized, consumer-based
model.”).
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potential patients in these groups view fertility care, but it also has the potential to
uncover unstated values held by the clinics that created the websites. Part IV
discusses the data relating to access to ART, finding, for instance, that almost every
clinic’s website that has an image of a baby on it has an image of a white baby.
Part V discusses the third goal of the study—assessing the success of the
industry’s attempts at self-regulation in advertising. The American Society for
Reproductive Medicine (ASRM) is a “multidisciplinary organization dedicated to
the advancement of the art, science, and practice of reproductive medicine” that is
affiliated with SART.12 For the past thirteen years, ASRM has created advertising
guidelines that it requires its members to follow. Despite the guidelines being
mandatory for members, Part V discusses how a large number of ASRM member
clinics are not complying with the guidelines. Studies of fertility clinics have
repeatedly found that clinics do not comply with self-regulation, but members of
the fertility business and academic commentary continue to insist that selfregulation, and not legal intervention, offers the best hope for ensuring clinics meet
minimal standards. Part V describes how in the context of advertising, selfregulation has utterly failed. As just one example, almost 40% of clinics did not
state the method the clinic used for calculating its success rate. If self-regulation
fails in this context where compliance can easily be assessed, it casts doubt on the
sufficiency of self-regulation in this industry more generally.
In light of the evidence uncovered in the study, I conclude by offering new
directions for policymakers and the industry to consider as they continue to try to
keep pace with new developments in the field of ART. Because of the problems
associated with self-regulation in the field, I suggest that lawmakers should
consider bolstering consumer protection measures to ensure that clinics advertise
truthfully. But, for some existing practices, legal solutions are inapt, so I suggest
regulations the industry could consider requiring its members to follow.
I. METHODOLOGY
To assess fertility clinic websites, three research assistants and I engaged in a
summative content analysis of the websites by making qualitative interpretations of
the material presented and quantitative counts of the coded information.13 I
identified which clinics to include in the study by using the Society for Assisted
Reproductive Technology (SART) website which lists its members by state.14 The
SART listing contains most clinics’ website addresses, but for those that did not list
a website, we obtained the website addressess by using standard Internet search
engines or by calling the clinics directly.

12. American Society for Reproductive Medicine, About Us: Mission Statement,
ASRM.ORG, http://www.asrm.org/mission/.
13. This approach mirrors prior work. See, e.g., Jack Y.J. Huang, Federico Discepola,
Haya Al-Fozan & Togas Tulandi, Quality of Fertility Clinic Websites, 83 FERTILITY &
STERILITY 538, 539 (2005); Katherine M. Johnson, Excluding Lesbian and Single Women?
An Analysis of U.S. Fertility Clinic Websites, 35 WOMEN’S STUD. INT’L F. 394 (2012).
14. Society for Assisted Reproductive Technology, IVF Success Rates: National
Summary, SART.ORG, http://www.sart.org/find_frm.html.
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Using SART’s listing, we reviewed information for 381 clinics. Of those 381,
only nine clinics did not have websites, meaning 97.64% (n=372) of fertility clinics
belonging to SART currently have websites. The number of clinics with websites
has continued to increase. In 2005, 66% of clinics had websites; in 2007, 80% had
websites; and another study from 2012 found 96% had websites.15
I developed a detailed protocol that asked team members to input codes and
textual material from the websites into an Excel spreadsheet. I decided which
things to code based on a review of the literature surrounding ART, which revealed
the concerns past work has raised about clinic behavior, and a pilot study, which
coded some of the information we obtained on hundreds of websites several years
ago and suggested additional items to evaluate. To ensure we all approached the
study in the same way, I trained each research assistant how to follow the protocol,
I coded one website with the assistant to practice, I answered all questions about
coding by group emails, and I reviewed the completed spreadsheet to identify any
aberrations.
For most topics, the research team member looked at the Home page of the
clinic’s website and the About page (or its equivalent) on the website and answered
yes/no questions about whether specific marketing information was present on the
website. If the marketing information was present, the researcher cut and pasted
specific quotations from the website that contained the marketing information. We
counted any statement as advertising, whether it appeared to be purely
informational or persuasive in nature, because even physicians working in fertility
clinics recognize that clinics use the “information” on websites as advertising.16 For
some topics, team members searched the clinic’s entire website for the information.
Overall, we coded sixty data points for each clinic. To analyze the data after they
were collected, I used Microsoft Excel and Stata.
There are several limitations on my research design. First, because I only
evaluate the websites of SART members, my findings do not represent the entire
universe of U.S. fertility clinics. A small number of clinics are not SART members,
and I cannot provide any information about their websites. However, roughly 95%
of clinics are members of SART, so the study captures the vast majority of
clinics.17
Second, my approach misses some information presented online by clinics. In
general, we only coded information on the Home and About pages, missing other
pages, and we did not code information on social networking sites, which 30% of
clinics use.18 I limited our observations to the Home and About pages because some
websites had a large number of pages, which would make the project unduly
burdensome. Also, because the Home page is the first page potential patients see
and because the About page is a probable place people seek information about the
clinic, the information on these two pages is the most likely to be salient to patients.

15. Omurtag et al., supra note 6, at 89, 91.
16. Tarun Jain & Robert L. Barbieri, Website Quality Assessments: Mistaking Apples for
Oranges, 83 FERTILITY & STERILITY 545, 546 (2005) (“Although there might be exceptions,
the primary function of fertility clinic websites is to describe their services, with the goal of
attracting more patients to use those services (a classic advertising model).”).
17. Huang et al., supra note 13, at 543.
18. Omurtag et al., supra note 6, at 89.
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Finally, I did not evaluate inter-rater reliability, so it is possible that different
members of the research team coded information differently. Yet, the protocol did
not generally leave any room for subjective interpretations, so the risk of disparate
coding is remote. Similar studies in the past also did not report inter-rater reliability
assessments.19
II. HOW DO FERTILITY CLINICS MARKET THEIR SERVICES?
This Part presents data on one of the core issues this study hopes to address—
how do clinics market their services? This Part attempts to answer the question by
cataloging the different features that clinics highlight on their websites. I group
these different features into four broad categories: nonpropositional content,
attributes of care, third-party assessments of the clinics, and financial information.
Past research has focused on small aspects of fertility advertising20 or mentioned
advertising in passing,21 but no studies have undertaken a broad survey of how
clinics advertise their services.
Websites are an important form of advertising because clinics communicate
information to persuade potential patients without having to explicitly advertise.
People generally dislike advertising,22 and they distrust it.23 Thus, companies
sometimes disguise what is really advertising in other formats like editorials to
make it more believable to consumers.24 Clinic websites often integrate
“supposedly objective medical information” and “commercial interests,” creating
an important source of advertising for clinics.25
Understanding how fertility clinics market their services on websites has the
potential to reveal two conflicting types of information about the interaction
between patients and clinics. On the one hand, it might provide information about
what patients think is important about clinics. On the other hand, it might only
reflect clinics’ attempts to frame the interaction in a way that draws patients even

19. E.g., Huang et al., supra note 13, at 543 (“[T]he interrater reliability was not
assessed. Nevertheless, because the websites were evaluated according to a set of objective
criteria, we believe that interrater reliability should not be a significant factor in this study.”).
20. See id. at 542 (addressing advertising of success rates).
21. E.g., THE PRESIDENT’S COUNCIL ON BIOETHICS, supra note 2 at 153 (“ART clinics
advertise for business, emphasizing the range of procedures they offer to infertile couples.”).
22. Eric Goldman, A Coasean Analysis of Marketing, 2006 WIS. L. REV. 1151.
23. REBECCA TUSHNET & ERIC GOLDMAN, ADVERTISING & MARKETING LAW: CASES AND
MATERIALS 8 (2012).
24. Id. at 71 (“Consumers frequently treat advertising as less credible than editorial
content. A 2005 study by Jansen and Resnick illustrates this phenomenon. Consumers were
shown multiple sets of Internet search results, some of which were labeled as advertising.
Although the search results were identical, consumers rated the unlabeled search results as
more relevant than the labeled results. . . . In other words, the label ‘advertising’ singlehandedly caused consumers to think the content was less relevant. For this
reason . . . advertisers have incentives to make ads look like editorial content, sometimes by
mimicking a publication’s font and layout.” (citations omitted)).
25. Robert Klitzman, Beata Zolovska, William Folberth, Mark V. Sauer, Wendy Chung
& Paul Appelbaum, Preimplantation Genetic Diagnosis on In Vitro Fertilization Clinic
Websites: Presentations of Risks, Benefits and Other Information, 92 FERTILITY & STERILITY
1276, 1283 (2009).
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though the patient may have selected another clinic if they had better information
or the information had been presented differently. Determining which of these
categories the advertising falls within is obviously a difficult task.
First, the features that clinics choose to advertise might reveal the factors that
they think patients use to decide which clinic to select for care. Because clinics
have a financial incentive to understand patient decision making, clinics’
perceptions of what patients value likely mirror how patients actually decide on
their fertility clinic.
Very often people make decisions based on one or two attributes they consider
most important.26 Lexicographic decision making is a frequent shortcut people use
in which the decision maker picks one attribute and selects the product or service
based on which one excels in that attribute.27 Assuming clinics are advertising
themselves with patients’ actual values in mind, this study can show which
attributes of fertility care are most important to people.
Some research exists on how people select a clinic, but it is based on surveys.28
While it is very valuable, survey-based research has limitations, such as people
misremembering events in the past or misreporting information. My approach
supplements this existing research by offering another way to ascertain why people
pick their clinics. While it of course presents other problems of its own, studying
businesses’ behavior is a useful proxy to determine how consumers think because
businesses often have more information about the consumer’s decision making than
the consumer.29

26. ROBERT B. CIALDINI, INFLUENCE: THE PSYCHOLOGY OF PERSUASION 274 (2007)
(“Very often in making a decision about someone or something, we don’t use all the relevant
available information; we use, instead, only a single, highly representative piece of the total.
And an isolated piece of information, even though it normally counsels us correctly, can lead
us to clearly stupid mistakes . . . .”).
27. See Amy B. Monahan, Value-Based Mandated Health Benefits, 80 U. COLO. L. REV.
127, 141 (2009) (“One of the simplest strategies, so-called lexicographic decisionmaking,
involves the purchaser choosing ‘the option with the highest ranking on the most important
attribute.’ If premiums are the most important factor to a health insurance purchaser, under
the lexicographic model he or she would simply select the health insurance plan that offers
the lowest premiums, disregarding other factors. A more complex decisionmaking model is a
modified weighted adding strategy, where the decisionmaker makes ‘trade offs among
desirable features of health insurance plans,’ but only includes high-importance factors in his
or her weighting.” (footnotes omitted)).
28. E.g., Amir Lass & Peter Brinsden, How Do Patients Choose Private In Vitro
Fertilization Treatment? A Customer Survey in a Tertiary Fertility Center in the United
Kingdom, 75 FERTILITY & STERILITY 893 (2001); Hani J. Marcus, Diana M. Marcus &
Samuel F. Marcus, How Do Infertile Couples Choose Their IVF Centers? An Internet-Based
Survey, 83 FERTILITY & STERILITY 779 (2005). Marcus et al. concluded that:
In conclusion, our study demonstrated that the two most important factors for
couples choosing an IVF center were the success rate and the quality of the
services provided by the center. Other important factors that affected the
decision were recommendation by a doctor, cost of treatment, distance from
home, and special expertise of the clinic.
Marcus et al., supra, at 781.
29. See, e.g., Oren Bar-Gill, The Behavioral Economics of Consumer Contracts, 92
MINN. L. REV. 749, 799 (2008) (“Credit card issuers often have more information about how
a consumer will use the credit card than the consumer herself. First, issuers have detailed
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But, on the other hand, understanding how clinics advertise might reveal
whether they are trying to exploit irrational decision making by patients by framing
the transaction in a way that emphasizes certain attributes of the clinic and
deemphasizes others. The rational actor model of human decision making assumes
that people have the ability to process information in a way that maximizes their
well-being. Yet, despite its theoretical appeal, “little hard data exist on how,
analytically, consumers make decisions about purchasing” fertility care.30 It is
possible that patients make suboptimal decisions that they would not otherwise
make if clinics advertised differently. Because clinic advertisements show how the
clinics frame the transaction, we can use the frequency of certain attributes that are
advertised to assess whether people are using faulty measures and whether clinics
are capitalizing on such mistakes.31 In suggesting that clinics could frame the
transaction to cause patients to make mistakes in selecting their clinics, I am not
suggesting that fertility patients are irrational in any unique way.32 Instead, I am
just employing the findings of behavioral economics that suggest all consumers act
with bounded rationality.33
Finally, the features that clinics advertise can affect patients’ actual experiences
at the clinic. Advertisements, even if they are promoting features of fertility care
that are irrelevant to consumers’ experiences with clinics, can cause consumers to
prefer the clinic.34 More surprisingly, advertisements can cause people to remember
the experience with the clinic in accordance with the advertised claims. For
instance, if a clinic claims to offer a caring environment, the patient may
experience and remember the clinic as caring. Rebecca Tushnet and Eric Godman
explain:
[A]ds can distort memory and perception, even when consumers have
direct experience with a product. Researchers showed people a false
claim of “no bitterness” in coffee and then had them taste coffee made
bitter by deliberate over-brewing. Consumers who’d seen the ad and
tasted the coffee rated the coffee as less bitter than consumers who had

statistics about card use; this includes statistics about card use in the consumer’s
demographic and socio-economic group. Second, issuers have information on the individual
consumer from the credit card application and from credit bureaus. Third, and most
importantly, since issuers often maintain long-term relationships with consumers, they
quickly obtain information about how this specific consumer uses this specific card.”
(footnotes omitted)).
30. Cf. Russell Korobkin, The Efficiency of Managed Care “Patient Protection” Laws:
Incomplete Contracts, Bounded Rationality, and Market Failure, 85 CORNELL L. REV. 1, 47
(1999) (making the comment in the context of consumer picking health insurance).
31. See id. at 55–56 (“In such situations, the choice of a decision-making approach
might depend highly upon which comparisons the presentation renders salient.”).
32. See generally Jody Lyneé Madeira, Woman Scorned?: Resurrecting Infertile
Women’s Decision-Making Autonomy, 71 MD. L. REV. 339 (2012).
33. For a review of the literature in the legal context, see generally Cass R. Sunstein,
Boundedly Rational Borrowing, 73 U. CHI. L. REV. 249 (2006).
34. See Gregory S. Carpenter, Rashi Glazer & Kent Nakamoto, Meaningful Brands
From Meaningless Differentiation: The Dependence on Irrelevant Attributes, 31 J.
MARKETING RES. 339 (1994) (finding that consumers preferred products after seeing
advertisements promoting irrelevant attributes despite the fact that the consumers were told
that the attributes promoted were irrelevant).
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only tasted the coffee. Even though the tasting had some effect on the
first group’s opinions, they still ended up being affected by the ad in the
face of directly contradictory experience. This result—that ads can
change memories, even memories of direct experiences—has been
confirmed in numerous other contexts by other researchers. . . . People
generally play along with advertising, making efforts to confirm
advertising-generated expectations and to avoid feeling like a dupe who
believed an untrue claim.35
Thus, studying the attributes clinics promote can also offer insight into how
patients experience their fertility care.
After describing the different types of advertising clinics use, I compare
academic and private clinics to understand how these types of clinics advertise
differently. Also, I compare clinics in states that mandate that insurance companies
cover infertility with states that do not have such a mandate.
A. Advertising that Lacks Informational Content
As a primary matter, some of the advertising we observed did not communicate
propositional information but instead communicated primarily emotional content to
the observer. Looking just at the Home page of each fertility clinic’s website, we
coded whether the first page had images of babies and whether it used the words
“dream” or “miracle.” Of the 372 clinics with websites, 79.03% (n=294) presented
images of babies on the Home page of their websites; 30.11% (n=112) used the
word “dream” on the Home page; and 8.87% (n=33) used the word “miracle.”
Presenting images of babies could have several effects on potential patients.
First, it is possible that customers will disregard the costs of the fertility services in
light of the value of children. Patients may be unwilling to commodify children, so
they are unable to assess the costs of fertility care versus the value of a child.
Russell Korobkin observes:
Research indicates that a primary way in which consumers attempt to
avoid such negative affect is to adopt selective or noncompensatory
decision-making strategies, which enable them to avoid the explicit
trade offs that a compensatory, nonselective approach requires.
Adopting a “choose-the-cheapest-car” strategy can help a consumer to
avoid the emotional consequences associated with determining whether
to pay an additional $500 for a car with an airbag. The desire to avoid
explicit trade offs can be heightened when a strong social norm
militates against commodifying one or more of the features at issue. For
example, if individuals believe that sacrificing environmental quality
for money or comfort is wrong, they will be less likely to use a
compensatory strategy to determine whether to purchase a car that is

35. TUSHNET & GOLDMAN, supra note 23, at 28 (citing Jerry C. Olson & Philip A.
Dover, Cognitive Effects of Deceptive Advertising, 15 J. MARKETING RES. 29 (1978));
Kathryn A. Braun, Postexperience Advertising Effects on Consumer Memory, 25 J.
CONSUMER RES. 319 (1999).
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cheap and luxurious or one that is expensive and uncomfortable but
emits less carbon monoxide.36
Placing the focus on a picture of a baby as a noncommodity may displace concerns
about cost in customers’ minds. This observation echoes the criticism that clinics
frame their relationship with patients as noncommercial, another means of
preventing more explicit awareness of costs concerns.37
Another effect of images of babies is that the images might suggest the outcome
of treatment—a successful pregnancy. Advertising scholars note that
advertisements that present images and allow viewers to draw their own
conclusions are more persuasive to customers than direct claims or even verbal
metaphors.38 If patients see children and come up with an association between
treatment and pregnancy on their own, they are more likely to act on the
information.39 Thus, it is possible that images of successful pregnancies are even
more persuasive than clinics’ frequent claims about their success rates. However,
the preoccupation with success rates in the literature on fertility clinic advertising
has caused scholars to neglect another, potentially more powerful, mechanism
through which clinics suggest that they have high success rates—pictures of
success.40
The criticisms of using the words “dream” and “miracle” fall in line with this
second criticism of pictures of babies. Scholarship has criticized clinics for using
the word “miracle” because it creates a false hope for patients.41 Similarly, focusing
on dreams, academics contend, causes patients to underestimate the costs involved
in fertility treatments.42

36. Korobkin, supra note 30, at 55.
37. See Krawiec, supra note 3, at 213 (“For their part, fertility centers do little to alter
the perception that their relationship with infertile couples is a non-commercial one,
highlighting instead their willingness and ability to help infertile couples realize their dreams
of conception. . . . Although marketing rhetoric of this sort is hardly unique, particularly in
the health care field, it does highlight a common trend evident across all sectors of the baby
market—a pretense that profit-seeking and market forces are, at best, secondary
considerations in matters so sacred as reproduction and parenthood.”).
38. TUSHNET & GOLDMAN, supra note 23, at 30–31.
39. See id.
40. See infra notes 41–49 and accompanying text.
41. Catherine A. Clements, What About the Children? A Call for Regulation of Assisted
Reproductive Technology, 84 IND. L.J. 331, 348 (2009) (“ART’s ‘wild west’ status is
particularly evident when a review of a local fertility clinic Web site proclaims proudly on
its banner: ‘Expect a Miracle!’ Despite examples of such advertising that might give false
hope to infertility patients, some insist that the industry can police itself.” (footnotes
omitted)); Developments in the Law—Medical Technology and the Law, 103 HARV. L. REV.
1519, 1539–40 (1990) (“Both clinics and the media have portrayed IVF as a technique that
combines low risk with high success. As a result, many people enter the clinics
unrealistically anticipating immediate success. . . . By nevertheless hailing IVF as a ‘miracle
cure’ and ‘scientific breakthrough’ providing hope for the infertile, media reports reinforce
the importance of the biological component of parenthood.” (footnotes omitted)).
42. Teresa Stanton Collett, Whose Life Is It Anyway?: Texas Public Policy and
Contracts to Kill Embryonic Children, 50 S. TEX. L. REV. 371, 371–72 (2009) (“Fertility
clinic advertisements, adorned with pictures of happy infants and their parents, promise what
seems unattainable, yet so desirable, to infertile couples who see children as an integral part
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B. Attributes of Care
In addition to these nonpropositional forms of advertising, clinics promote
themselves based on specific characteristics of the care that they provide. To obtain
an understanding of what attributes of care clinics most frequently emphasize, we
recorded each time a clinic’s Home page or About page mentioned that the clinic:
(1) had excellent technology; (2) provides personal, caring treatment; (3) had high
quality doctors; (4) had access to donors for patients; (5) had been the “first” to
make some advance or offer some treatment in the nation or a region; (6)
specialized in “hard to treat” cases; (7) had large facilities; and (8) was equipped to
help older patients. To compare the frequency with which these attributes of care
appeared with claims about success rates, I also present here the number of
websites mentioning success rates on the Home and About pages. The results are
summarized in Table 1.
Table 1: Attributes of Care Advertised on Fertility Clinic Websites
Attribute of Care
Percentage Mentioning Number (of 372 websites)
Excellent Technology
83.87
312
Personal Care
75.00
279
High Quality Doctors
69.89
260
Donors
56.45
210
Success Rates
55.65
207
“Firsts”
25.81
96
Hard to Treat Cases
18.55
69
Facilities
12.37
46
Older Patients
5.91
22
The fact that so many clinics advertise features other than success rates
undermines a central belief that has animated scholarship about, and legal
intervention into, the fertility business. Scholars and legislators have traditionally
thought that success rates are the most salient factor in patients’ minds when
picking a clinic. As one example, a past study of clinic websites concluded that
“apart from advertising the availability of donor egg programs and embryo
cryopreservation, IVF success rates were the most commonly advertised feature on
fertility clinic websites.”43
Concerns about success rates have dominated discussions of consumer
protection for ART by legal academics for more than two decades.44 The only
of their lives together. . . . . Yet the lived experiences of many couples who have attempted
to create a child through IVF are far from the idyllic dreams that led them to the clinics.”).
43. Mary E. Abusief, Mark D. Hornstein & Tarun Jain, Assessment of United States
Fertility Clinic Websites According to the American Society for Reproductive Medicine
(ASRM)/Society for Assisted Reproductive Technology (SART) Guidelines, 87 FERTILITY &
STERILITY 88, 92 (2007).
44. See, e.g., Developments in the Law—Medical Technology and the Law, supra note
41, at 1541 (“The distorted reporting of success rates exemplifies the industry’s willingness
to place its own interests above its patients.”); Jean Macchiaroli Eggen, The “Orwellian
Nightmare” Reconsidered: A Proposed Regulatory Framework for the Advanced
Reproductive Technologies, 25 GA. L. REV. 625, 648 (1991) (“Upon entering a program in
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federal law, The Fertility Clinic Success Rate and Certification Act of 1992,45 as
well as several state laws, take aim at accurate reporting of success rates.46 Success
rates have even made appearances in court decisions.47
Ethical opinions by ASRM about advertising have been primarily focused on
success rates. The first guideline in 1999 only discussed advertising of success
rates.48 The first sentence in both the 2004 and 2009 ASRM advertising guidelines
also reveals that those versions of the guidelines are essentially focused on success
rates: “Both patients and referring physicians have a right to know pregnancy rates
derived from assisted reproduction programs.”49
advanced reproductive technology, the couple’s primary need is to obtain accurate, realistic
information regarding the available procedures and their likelihood of success in the
program.”); Michele Goodwin, Prosecuting the Womb, 76 GEO. WASH. L. REV. 1657, 1722
(2008) (discussing how clinics manipulate their success rates); Jaime Staples King, Living
ART, 23 HASTINGS WOMEN’S L.J. 73, 73–74 (2012) (citing “high success rates” as the
driving factor behind the author’s choice of a fertility clinic); Alicia Ouellette, Arthur
Caplan, Kelly Carroll, James W. Fossett, Dyrleif Bjarnadottir, Darren Shickle & Glenn
McGess, Lessons Across the Pond: Assisted Reproductive Technology in the United
Kingdom and the United States, 31 AM. J.L. & MED. 419, 424–28 (2005) (describing the
deficiencies of the laws governing disclosures of success rates in the United States); Usha
Rengachary Smerdon, Crossing Bodies, Crossing Borders: International Surrogacy Between
the United States and India, 39 CUMB. L. REV. 15, 29 (2008) (noting that criticisms of ART
in India include “inflation of success rates”); Urška Velikonja, The Costs of Multiple
Gestation Pregnancies in Assisted Reproduction, 32 HARV. J.L. & GENDER 463, 482–83
(2009) (explaining the federal law regarding success rates and the “perverse incentives” it
creates); Stephanie J. Hong, Note, And “Cloning” Makes Three: A Constitutional
Comparison Between Cloning and Other Assisted Reproductive Technologies, 26 HASTINGS
CONST. L.Q. 741, 755–57 (1999) (describing the Fertility Clinic Success Rate and
Certification Act of 1992 and noting that “the Act’s reforms are not particularly novel or
efficacious”).
45. 42 U.S.C.A. § 263a-1 (West 2011) (requiring that fertility clinics report pregnancy
success rates to the Centers for Disease Control using a specified format).
46. See, e.g., 18 PA. CONS. STAT. § 3213(e) (2012) (“All persons conducting, or
experimenting in, in vitro fertilization shall file quarterly reports with the department, which
shall be available for public inspection and copying, containing the following
information: . . . (5) Number of eggs fertilized . . . (6) Number of women implanted with a
fertilized egg.”); VA. CODE ANN. § 54.1-2971.1 (2012) (“Before a physician commences
treatment of a patient by in vitro fertilization, gamete intrafallopian tube transfer, or zygote
intrafallopian tube transfer, including the administration of drugs for the stimulation or
suppression of ovulation prefatory thereto, a disclosure form shall have been executed by the
patient which includes, but need not be limited to, the rates of success for the particular
procedure at the clinic or hospital where the procedure is to be performed. The information
disclosed to the patient shall include the testing protocol used to ensure that gamete donors
are free from known infection with human immunodeficiency viruses, the total number of
live births, the number of live births as a percentage of completed retrieval cycles, and the
rates for clinical pregnancy and delivery per completed retrieval cycle bracketed by age
groups consisting of women under thirty years of age, women aged thirty through thirty-four
years, women aged thirty-five through thirty-nine years, and women aged forty years and
older.”).
47. Karlin v. IVF Am., Inc., 712 N.E.2d 662, 664–65 (1999).
48. Huang et al., supra note 13, at 542.
49. Soc’y for Assisted Reprod. Tech. Exec. Council, SART Policy for Advertising by
ART Programs, available at http://www.sart.org/uploadedFiles/Affiliates/SART/Members/
Executive_Council/sart-advertising-policy-4-2009.pdf [hereinafter SART Executive
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Significantly, however, this study of clinic websites reveals that more clinics
emphasize the technology the clinic offers; the personal, caring approach the clinic
takes; the high quality of the doctors the clinic employs; and the access the clinic
offers to donors than the clinic’s success rates. The frequency with which clinics
highlight these other features should widen the myopic fixation that scholarship and
policymaking has had on success rates. As discussed above, this finding might
demonstrate that other factors are important to patients, if we assume clinics are
attempting to match patients’ informational needs. Alternatively, it might reflect
clinics’ attempts to frame the transaction to emphasize attributes they think will
make them attractive to patients. For instance, if a clinic’s success rate were lower
than its competitors, perhaps the clinic would emphasize other subjective factors
like its technological prowess or quality of its doctors to focus patients’ attention on
those attributes instead of its lower success rate. In either case, policy makers need
to account for clinics’ behavior of advertising factors other than success rates.
C. Third-Party Assessments of the Clinic
Another category of advertising that clinics’ websites rely on is advertising
based on third-party assessments of the clinics. Looking just at the Home and
About pages of the websites for each classification, we recorded every time the
clinic mentioned that the doctor or clinic was board certified. These certifications
came from organizations such as the American Board of Obstetrics & Gynecology.
Second, we noted if the clinic mentioned it was part of a professional association,
most often ASRM. Next, we looked for other endorsements by another type of
group. This classification included endorsements by “Top Doctors” lists in a
region, by magazines, and by the Patients’ Choice Award. Finally, we noted the
number of websites that included patient testimonials. These data are presented in
Table 2.
Table 2: Frequency of Home and About Pages Discussing Third-Party
Assessments
Percentage
Number
Board Certification
51.08
190
Professional Associations
37.10
138
Other Third-Party
26.61
99
Endorsements
Patient Testimonials
43.01
160
Third-party assessments in the first three classifications are significant from a
practical standpoint because patients may lack the ability or knowledge to assess
what clinic is best for them. The sort of third-party endorsements in the first three
groups in Table 2 act like information intermediaries or expert conduits of medical
information who “locate information relevant to the parties they represent, analyze
and distill it, and communicate it fairly and accessibly to individual consumers.”50
Council]; Practice Comm. of the Soc’y for Assisted Reproductive Tech. & the Am. Soc’y for
Reprod. Med., Guidelines for Advertising by ART Programs, 82 FERTILITY & STERILITY 527,
527 (2004).
50. William M. Sage, Regulating Through Information: Disclosure Laws and American
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These intermediaries are advertising authority figures to which people are likely to
respond.51
Take board certification as one example of an information intermediary. Studies
reveal that whether a physician is board certified is an important factor in how
consumers choose physicians. For instance, a study analyzing twenty-three factors
consumers use to select their primary care physician found that the most important
factor was whether a physician was board certified.52 Similarly, another study
found that half of health care consumers would be very likely to find another
physician if they found their physician’s board certification had expired.53 Another
study found that of the nearly 4,000 consumers surveyed, 82% found board
certification for a physician to be an “important or very important” factor in
selecting physicians for their children.54
Although they do not present any expertise, patient testimonials are important
because of the principle of social proof. Social psychologist Robert Cialdini
explains: “[O]ne means we use to determine what is correct is to find out what
other people think is correct. . . . The tendency to see an action as more appropriate
when others are doing it normally works quite well.”55 He uses the example of
laughter tracks and television. Despite the fact most people dislike canned laughter,
studies show that people rate humorous material as funnier if it is accompanied by
canned laughter.56 In the same way, patient testimonials help the clinic indirectly
communicate how it wants potential patients to act. The efficacy of patient
testimonials is demonstrated not only by their presence on clinics’ websites but also
by the federal law governing them. The Federal Trade Commission (FTC) requires
that advertisers must be able to substantiate any claims made by patients in
testimonials the advertiser uses.57
Health Care, 99 COLUM. L. REV. 1701, 1737 (1999). Another way of looking at the function
of board certification, professional associations, and endorsements is as trustmarks:
With upstream filtering, on the other hand, experts review and evaluate the
content. The result of such an approach, which has been suggested by several
people, could be the creation of a[n ASRM] ‘trustmark’ mechanism. . . . The
time is ripe for the ASRM, perhaps in partnership with consumer organizations
such as RESOLVE, INCIID, and AFA, to launch a task force to study the
problem of managing infertility information on the Internet and proposing
useful solutions.
Yakov M. Epstein & Helane S. Rosenberg, Assessing Infertility Information on the Internet:
Challenges and Possible Solutions, 83 FERTILITY & STERILITY 553, 555 (2005).
51. Cf. CIALDINI, supra note 26, at 213.
52. Brian H. Bornstein, David Marcus & William Cassidy, Choosing a Doctor: An
Exploratory Study of Factors Influencing Patients’ Choice of a Primary Care Doctor, 6 J.
EVALUATION CLINICAL PRAC. 255 (2000).
53. THE GALLUP ORG. FOR THE AM. BD. OF INTERNAL MED., AWARENESS OF AND
ATTITUDES TOWARD BOARD-CERTIFICATION OF PHYSICIANS (2003).
54. Gary L. Freed, Kelly M. Dunham, Sarah J. Clark & Matthew M. Davis, Perspectives
and Preferences among the General Public Regarding Physician Selection and Board
Certification, 156 J. OF PEDIATRICS 841, 843 (2010).
55. CIALDINI, supra note 26, at 116.
56. Id. at 115–16.
57. TUSHNET & GOLDMAN, supra note 23, at 202 (“FTC Guides Concerning the Use of
Endorsements and Testimonials in Advertising, § 255.2 Consumer Endorsements (a) An
advertisement employing endorsements by one or more consumers about the performance of
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D. Financial Information
The final type of advertising clinics rely on is financial information. Clinics
advertise themselves based on the prices of the care they offer, the insurance they
accept, and the access they provide to financing arrangements.
1. Price
Price is usually one of the most important terms in a consumer transaction,58 so
we might guess that price would be an important point of competition between
fertility clinics that the clinics highlight on their websites. The facts that most
people have to pay for fertility treatments out of pocket and that the treatments are
expensive bolster this intuition.
As it turns out, however, price plays only a very minor role in advertising
fertility services through clinics’ websites. Only 27.15% of websites (n=101) list
some sort of actual price for IVF, with the vast majority not providing any
information on the amount IVF costs at the clinic. Almost twice that number,
54.84% (n=204), market themselves because of price on the Home page or the
About page of the clinics’ websites (despite not listing the actual price). Still, given
the usual preeminence of price in consumer decision making, it is surprising that
only half of the websites mention price at all as a reason to select the clinic.
There are several possible explanations for why more websites do not list prices
or advertise the clinics because of cost. First, it could reflect the general aversion
medical professionals have for discussing prices with patients.59 Second, the lack of
pricing information might result from an inability to predict ahead of time the cost
of treatment because each patient’s situation is different, and accurate price
quotations can only be obtained after actually seeing a doctor.60 Another possible
explanation, however, is that most clinics do not think cost is an important factor in
patients’ decisions about their fertility provider or that most clinics do not want
patients to know the cost of the treatment upfront because it might make them less
inclined to seek treatment. It is difficult to think that patients are unconcerned about
price, and it is difficult to construct a rational-choice explanation for clinics’ failure
to discuss price on their websites. Thus, it seems more likely that clinics are
purposefully refusing to present price information to focus patients’ attention away
from price.

an advertised product or service will be interpreted as representing that the product or service
is effective for the purpose depicted in the advertisement. Therefore, the advertiser must
possess and rely upon adequate substantiation, including, when appropriate, competent and
reliable scientific evidence, to support such claims made through endorsements in the same
manner the advertiser would be required to do if it had made the representation directly, i.e.,
without using endorsements. Consumer endorsements themselves are not competent and
reliable scientific evidence.”).
58. Oren Bar-Gill, Bundling and Consumer Misperception, 73 U. CHI. L. REV. 33, 45
(2006).
59. Mark A. Hall & Carl E. Schneider, Patients as Consumers: Courts, Contracts, and
the New Medical Marketplace, 106 MICH. L. REV. 643, 654–55 (2008).
60. Carl E. Schneider & Mark A. Hall, The Patient Life: Can Consumers Direct Health
Care?, 35 AM. J.L. & MED. 7, 20 (2009).
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Clinics that do promote themselves because of price use a variety of approaches.
Many clinics straightforwardly assert they are less expensive than competitors.
Problematically, some clinics claim to have lower prices but fail to list the price so
that consumers can assess the truthfulness of the claim.61 Along the same lines, one
clinic notes the fact that its prices are competitive and that it does not have hidden
fees, despite the fact it does not list its fees.62
The high cost of their services does not appear to dissuade some clinics from
advertising that they are cost-conscious providers. One clinic notes that it offers the
“most affordable fees possible,” despite the fact that it charges $11,750 for an IVF
cycle, nearly the highest price in the country.63 Another clinic charging $9,000 for
one IVF cycle, well above the average cost, claims to have “the most competitive
pricing in the greater Washington area.”64 With so little pricing information
available, it would be hard for consumers to assess these claims.
In addition to general claims about low costs, other websites market the clinic
based on price by touting the clinic’s IVF refund program.65 Finally, clinics
embrace common advertising techniques such as “limited-time offers”66 or
discounts for certain groups, like military personnel.67
Even when clinics do list prices, it is extremely difficult to compare prices
between clinics because they bundle their services differently. Clinics mostly
present a single price for IVF packages, but they include different services in these
packages.68 Some are very inclusive, offering a price for packages with the required
monitoring, egg harvesting, embryo transfer, intracytoplasmic sperm injection
(ICSI), assisted hatching, and cryopreservation. Others, however, quote prices for
plans that include almost no services, not even monitoring.69 Other clinics are less
clear, stating prices without providing any information about what is included. One
website states, “IVF for $5,000. Reduces the cost of a cycle with Shared IVF.”70
The website, however, provides no further breakdown or explanation of the price of
services. Finally, some websites list the cost of participating in an IVF refund
program but do not list the price for treatments outside the plan,71 so patients are
left to only compare the one clinic with other clinics offering refund programs.

61. E.g., Observation 368 (stating “[o]ur fertility services consistently cost 1/3 less than
the big, corporate fertility clinics” without listing a price); Observation 357 (noting that the
clinic’s “costs for IVF are among the lowest in the country” without stating a price).
62. Observation 361 (“In these challenging times our prices remain competitive and
extremely fair. All inclusive package prices insure that our patients will not be surprised by
hidden extra charges that can inflate treatment cost significantly.”).
63. Observation 82.
64. Observation 355.
65. E.g., Observation 372 (“Financial Flexibility: [The clinic] now offers options for
shared risk IVF through our Shared Success Program.”). See infra Part II.D.3 (discussing
IVF refund programs).
66. Observation 125; Observation 168.
67. Observation 349.
68. Ha T. Tu & Jessica H. May, Self-Pay Markets in Health Care: Consumer Nirvana
or Caveat Emptor?, 26 HEALTH AFF. w217, w222 (2007).
69. Observation 223.
70. Observation 7.
71. E.g., Observation 217; Observation 258.
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The inability to price shop presents a significant market failure. If patients do
not have access to pricing information without going into a clinic for an evaluation
or at least calling the clinic to get pricing information, the search costs may be too
high to enable a functioning market. Moreover, if patients lack the ability to
compare clinics even when they do know the relevant pricing and packages, the
market cannot generate competitive pressure to lower costs.
Because we reviewed the price of every clinic that lists its price on its website, I
am able to present data on the average cost of IVF in the United States. To try to
obtain price figures that were comparable between different websites, we recorded
the price of one cycle of IVF using fresh (not previously frozen) embryos, but not
including the cost of ICSI, assisted hatching, or medications. For many websites,
this required that we carefully read what is included in the listed price and subtract
or add the cost of different services. If we found a price listed that included the cost
of ICSI or assisted hatching but did not list the price of those services separately, I
subtracted $1200 for ICSI and $1000 for assisted hatching, basing those rough
estimations on the cost of the services at several clinics.72 Also, several websites
listed prices that only included doctors’ fees or “mini-IVF” cycles73 or excluded
monitoring, so I excluded those from my analysis of prices. Based on the remaining
ninety-two websites, the mean price was $8117.25, the median price was $8360,
the lowest price was $4000, and the highest price was $12,415. These price figures
are lower than what is commonly reported, most likely because my figures do not
include ICSI, assisted hatching, or medications. Adding those common services
would raise the mean price to $12,317.25 and the median price to $12,560,
assuming medications cost $2000, ICSI costs $1200, and assisted hatching costs
$1000.
2. Insurance
Only 16.40% (n=61) of clinics mention insurance on their Home and About
pages as a means of advertising the clinic. Several factors may explain the low
frequency. This finding could merely reflect the fact that websites contain
information about insurance on financial pages and not their Home or About pages,
but it is surprising more websites do not highlight insurance on their central pages
if insurance is an important way to pay for fertility care.74 Or, it could be that
websites do not mention it because so few patients have insurance that covers the

72. See Observation 9 (listing the cost of ICSI as $1525); Observation 374 (listing the
cost of ICSI as $900); Observation 349 (listing the cost of ICSI as $1990 and the cost of
assisted hatching as $1290); Observation 355 (listing the cost of ICSI as $1500 and the cost
of assisted hatching as $950).
73. E.g., Observation 229; Observation 235.
74. Judith F. Daar, Accessing Reproductive Technologies: Invisible Barriers, Indelible
Harms, 23 BERKELEY J. GENDER L. & JUST. 18, 38 (2008) (“Thus, it appears that
socioeconomic status, and to a lesser extent employment status, significantly affect one's
ability to access ART services in the United States. For wealthy individuals who can afford
to pay directly for these services, access, for the most part, appears to be wide open. For
individuals covered by private health insurance that includes infertility benefits, access
would again seem open, with limitations based on the patient's ability to afford co-payments
or non-covered services.” (footnote omitted)).
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procedures. But, even in states that mandate that insurance companies cover
infertility treatments, only 21.21% (n=14) mention the insurance plans they take on
the Home or About pages. This finding corresponds with past work that has found
that insurance mandates alone do not increase utilization rates.75
Clinics mentioning insurance primarily advertise themselves by noting that they
accept a wide variety of insurance plans.76 Also, clinics emphasize that they work
with patients to file the claims with insurance companies, often as part of their pitch
that they offer caring services.77 For instance, one website notes: “Our financial
coordinators are experts in healthcare insurance issues, especially those relating to
infertility benefits. This expertise allows them to serve as advocates for our
patients; knowing who to contact and what questions to ask to determine fertility
benefits.”78 Additionally, clinics seem to intend to mitigate concerns about cost by
suggesting that “patients find they have more insurance coverage than
anticipated.”79
3. Loans and Refund Programs
Two other important financial programs that fertility clinics advertise are loans
and IVF refund programs. Clinics emphasize their own ability to loan money to
patients or their relationships with third-party lenders to promote themselves,80 and
they offer, either directly or through a third party, IVF refund programs in which
the patient pays a higher fee upfront but is guaranteed either a pregnancy or a
refund.81 My current study did not evaluate the frequency at which clinics advertise
these two programs because prior work had already done so. In a prior study, I
found that, when evaluating all the pages of a website, 48.5% mentioned credit on
their websites, and of those mentioning credit, 52.4% marketed themselves because
of the credit or marketed the credit itself.82 Similarly, 35.4% of websites advertised
IVF refund programs.83

75. Id. at 37 (“In fact, studies show that private insurance mandates for fertility
treatment have little or no overall effect on the use of such treatments in the United States.
Researchers postulate that the reason for the low impact of private insurance mandates on
treatment utilization can be explained by examining the demographic characteristics of those
who are affected by changes in health insurance coverage. Because insurance mandates only
affect individuals who have access to private health insurance, this group is generally
wealthier and more likely to be employed than the general population. These are often the
same individuals who can access ART with their own resources; thus the marginal benefit
from insurance coverage tends not to increase usage among the insured.”).
76. Observation 201 (listing around fifty plans with which the clinic works);
Observation 233 (“[The clinic] accepts most major insurance plans . . . .”).
77. Observation 79 (“[W]e help with the emotional stresses of infertility, as well as with
insurance coverages and financial options.”).
78. Observation 51.
79. Observation 125.
80. See generally Jim Hawkins, Doctors as Bankers: Evidence from Fertility Markets,
84 TUL. L. REV. 841 (2010).
81. Jim Hawkins, Financing Fertility, 47 HARV. J. ON LEGIS. 115, 119 (2010).
82. Hawkins, supra note 80, at 861.
83. Hawkins, supra note 81, at 118.
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E. Comparing Academic Clinics’ and Private Clinics’ Advertising
In addition to understanding what clinics generally use to market themselves,
this study offers a way to compare the differences between advertising practices of
academic clinics and private clinics. Commentary has suggested that academic
medical centers should take the lead in promoting ethical practices,84 and this study
offers evidence of whether that recommendation is being followed in fertility clinic
advertisements.
Past studies have compared the quality of academic clinics’ and private clinics’
websites and the different levels of compliance with self-regulations.85 Abusief et
al., for instance, found that private clinics were more likely to publish success rates,
and were more likely to engage in illicit comparison marketing, but they were also
more likely to define the numerator and denominator of their success rates.86
For our study, to determine if a clinic was an academic or a private clinic, we
searched the entire website and deemed clinics to be academic if “they [are] either
university based and/or part of a hospital that had a graduate medical education
(GME) program (as listed within the clinic or hospital website).”87 20.43% (n=76)
of the clinics were academic clinics, and 79.57% (n=296) were private clinics.
Like Absuief et al., I found that, in several categories, there were differences
between advertising at academic clinics and private clinics, while in other
categories the differences were not significant. Results were tested for statistical
significance based on the chi-square test of independence, or for results that
generated numbers less than five, I used Fisher’s exact test. Results were
considered significant if the p-value was lower than .05. Table 3 summarizes the
comparisons.

84. See Troyen A. Brennan, David J. Rothman, Linda Blank, David Blumenthal, Susan
C. Chimonas, Jordan J. Cohen, Janlori Goldman, Jerome P. Kassirer, Harry Kimball, James
Naughton & Neil Smelser, Health Industry Practices That Create Conflicts of Interest: A
Policy Proposal for Academic Medical Centers, 295 JAMA 429, 430 (2006) (“Academic
medical centers, which include medical schools and thief affiliated hospitals, should provide
leadership for medicine in the United States. Just as pharmaceutical manufacturers look to
AMCs for influential advice and support, so does the medical profession. Academic medical
centers also have a major responsibility for training medical students and house staff.
Research reveals that the habits learned or acquired during training persist into practice.”).
85. Abusief et al., supra note 43.
86. Id. at 90 tbl.3.
87. Id. at 89.
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Table 3: Comparison of Advertising on Academic and Private Clinics’ Websites
Type of
Academic
Academic
Private
Private
p-value
Advertising
Percentage
Number
Percentage Number
Image of Baby
57.89
44
84.46
250
0.001
on First Page
“Miracle” on
5.26
4
9.80
29
0.264
Home Page
“Dream” on
23.68
18
31.76
94
0.207
Home Page
Excellent
82.89
63
84.12
249
0.795
Technology
Personal Care
63.16
48
78.04
231
0.008
High Quality
59.21
45
72.64
215
0.023
Doctors
Donors
42.11
32
60.14
178
0.005
Success Rates
39.47
30
59.80
177
0.001
“Firsts”
15.79
12
28.38
84
0.025
Hard to Treat
14.47
11
19.59
58
0.306
Cases
Facilities
10.53
8
12.84
38
0.585
Older Patients
3.95
3
6.42
19
0.588
Professional
19.74
15
41.55
123
0.001
Associations
Board
42.11
32
53.38
158
0.079
Certifications
Endorsements
14.47
11
29.73
88
0.007
Patient
19.74
15
48.99
145
0.001
Testimonials
Price
36.84
28
59.46
176
0.001
List Price
15.79
12
30.07
89
0.013
Insurance
11.84
9
17.57
52
0.229
Whether we think academic clinics are leading the way in ethical advertising of
course depends on what categories of advertising we think are ethical. Based on my
own preferences, the results are mixed. There is no significant difference between
the rates at which academic and private clinics use the words “dreams” or
“miracles,” suggesting they are not acting more ethically, but fewer academic
clinics use images of babies on their Home pages. Fewer academic clinics advertise
success rates, which have been associated with deception in the past, but on the
other hand, academic clinics are not leading the way to encourage price to be an
important competitive pressure. Fewer academic clinics than private clinics
advertise based on price or list the price of treatment on their websites.
F. Comparing Clinics in States with Mandated Coverage
In addition to comparing academic and private clinics, I compared clinics in
states with mandated insurance coverage of infertility and states without such
mandates in order to see if clinics advertised differently in these states.
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To do the comparison, I omitted Texas, California, Ohio, Louisiana, and New
York from the comparisons because these states do not neatly fall within either
category of mandated care or the absence of mandated care. Texas only requires
that insurance companies offer infertility coverage to employers (and not that
employers select such plans), and California, Ohio, Louisiana, and New York
mandate coverage but do not mandate that insurers cover IVF.88 Omitting these
clinics resulted in 135 clinics being dropped from the comparison. I treated
Arkansas, Connecticut, Hawaii, Illinois, Maryland, Massachusetts, Montana, New
Jersey, Rhode Island, and West Virginia as having mandated IVF coverage and the
rest as having no mandated coverage.89 Table 4 presents the results on the
categories for which there was a statistically significant difference.
Table 4: Comparison of Advertising on Clinics’ Websites in States with and
Without Mandated Insurance Coverage
Type of
Nonmandate Nonmandate
Mandate
Mandate p-value
Advertising
Percentage
Number
Percentage Number
Facilities
8.00
14
22.73
15
0.002
Price
55.17
96
37.88
25
0.017
Listing the
27.01
47
15.15
10
0.034
Price of IVF
Remarkably, it does not appear, for the most part, that merely having an
insurance mandate decreases the number of clinics advertising in different
categories. There were no significant differences in the number of clinics using
pictures of babies or the words “dream” or “miracle” to bring in patients. Also, it
was surprising that states with mandated insurance did not emphasize the insurance
plans that they accept more than clinics in states without mandated care.
Overall, this picture of fertility clinic advertising on the Internet offers a
comprehensive understanding of what factors clinics think patients value in their
fertility care and the factors that clinics believe they can emphasize to draw patients
to their clinics. Despite assumptions made in the past, success rates are not the only
feature of fertility care that the clinics selling ART emphasize. Instead, clinics
employ a variety of methods to entice consumers to come to them. The next section
talks about the opposite effect of advertising—how the content of clinics’ websites
discourages certain groups of patients from seeking fertility care.
III. ACCESS TO ART
Access to ART by racial minorities has been a major concern of academics
discussing ART. But, as Dorothy Roberts points out in an important essay, the

88. I. Glenn Cohen & Daniel L. Chen, Trading-Off Reproductive Technology and
Adoption: Does Subsidizing IVF Decrease Adoption Rates and Should It Matter?, 95 MINN.
L. REV. 485, 539–40 tbl.1 (2010). For a slightly different determination of which states
mandate coverage, see Valarie Blake, It’s an ART not a Science: State-Mandated Insurance
Coverage of Assisted Reproductive Technologies and Legal Implications for Gay and
Unmarried Persons, 12 MINN. J.L. SCI. & TECH. 651, 663–65 (2011).
89. Cohen & Chen, supra note 88, at 539–40 tbl.1.
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problem is that “[e]vidence is hard to come by.”90 This Part uses the data I obtained
from fertility clinics’ websites to assess the barriers these groups face in accessing
treatment. Websites can serve as a proxy for the cultural and organizational norms
in fertility markets and for clinics’ actual practices,91 so the information presented
about racial minorities offers some evidence concerning the current norms in
fertility treatment.
Racial minorities face financial barriers to accessing ART in states that do not
require insurance companies to cover ART because of the distribution of wealth
among racial groups.92 But even in states with comprehensive insurance coverage
mandated by law, African American and Hispanic women are underrepresented
among those seeking fertility treatments.93 The disparity between different groups’
participation in fertility treatments could be a result of a variety of factors that
website information cannot readily evaluate, such as doctors steering minorities
away from fertility treatments.94
For other potential causes, however, clinic websites could be a source of
information. Some scholars have suggested that minorities may experience a
cultural or lingual disconnect from fertility doctors because so few endocrinologists
are racial minorities or multilingual95 or because images of infertility in popular
culture do not reflect minority populations.96 Past commentary has suggested that
the picture of people experiencing infertility—figuratively and literally—is of
white people.97

90. Dorothy E. Roberts, Race and the New Reproduction, 47 HASTINGS L.J. 935, 949
(1996).
91. See Johnson, supra note 13, at 396.
92. See Khiara M. Bridges, On the Commodification of the Black Female Body: The
Critical Implications of The Alienability of Fetal Tissue, 102 COLUM. L. REV. 123, 161–62
n.147 (2002); David Orentlicher, Discrimination Out of Dismissiveness: The Example of
Infertility, 85 IND. L.J. 143, 181 (2010) (“When health-care insurance does not cover
infertility treatments and couples (or individuals) must pay out of pocket, then the significant
costs of these treatments mean that they tend to be reserved for wealthier, white couples who
can pay for them out of personal resources.”).
93. Tarun Jain & Mark D. Hornstein, Disparities in Access to Infertility Services in a
State with Mandated Insurance Coverage, 84 FERTILITY & STERILITY 221, 222 (2005).
94. Roberts, supra note 90, at 940.
95. Nanette R. Elster, ART for the Masses? Racial and Ethnic Inequality in Assisted
Reproductive Technologies, 9 DEPAUL J. HEALTH CARE L. 719, 729 (2005) (“Differences in
language and culture between infertility service providers and patients may be yet another
obstacle . . . .”).
96. Lisa Ikemoto has noted that procreative technology is nearly indistinguishable from
the stories about its uses. Lisa C. Ikemoto, The In/Fertile, the Too Fertile, and the Dysfertile,
47 HASTINGS L.J. 1007, 1020 (1996). If the images of infertility are dominated by whites,
this will affect the rate at which minorities seek treatment.
97. Elster, supra note 95, at 724 (“If one reads the newspaper, picks up a magazine or
flips on the nightly news, or any talk show, for that matter, the infertile look to be white,
middle to upper middle class couples or women, with relatively high levels of education.”);
Dorothy E. Roberts, The Genetic Tie, 62 U. CHI. L. REV. 209, 210 (1995) (“In one sense my
friend is right: the images that mark these controversies appear to have little to do with Black
people and issues of race. The tragedy of a rosy-cheeked girl torn from the adoptive couple
who spent years battling in court to keep her; the infertile suburban housewife’s agonizing
attempts to become pregnant via in vitro fertilization; the blue-eyed, blonde-haired baby held
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The first part of my assessment was to measure the literal images of fertility
treatments presented on fertility clinic websites. For every website that had pictures
of babies on the Home page, we coded the races of the babies.98 Of the 294
websites that presented images of babies, 62.93% (n=185) presented pictures of
only white babies, while 1.02% (n=3) presented images of only black babies,
0.34% (n=1) had an image of only a Latino baby, and 1.02% (n=3) had a picture of
only an Asian baby. If we include instances where white babies appear along with
babies of other races, 97.28% (n=286) of websites with pictures of babies have
pictures of white babies.99 The full results are presented in Table 5.
Table 5: Race of Babies on Clinics’ Home Pages
Race of Baby
Percentage
Number (of 294)
White Only
62.93
185
Black Only
1.02
3
Latino Only
0.34
1
Asian Only
1.02
3
White and Black
8.16
24
White and Latino
4.76
14
White and Asian
5.10
15
Black and Asian
0.34
1
Three or More Races
16.33
48
The fact that most websites present images of white babies presents two
different possible narratives. First, the fact that white babies appear with such a
high frequency might explain some of the reason for the disparity in utilization
rates for fertility care among races. As discussed in Part II, the principle of social
proof, social psychologists contend, drives unconscious behavior. This principle
works “most powerfully when we are observing the behavior of people just like us.
It is the conduct of such people that gives us the greatest insight into what
constitutes correct behavior for ourselves. Therefore we are more inclined to follow
the lead of a similar individual than a dissimilar one.”100 It is possible that pictures
up to television cameras as the precious product of a surrogacy arrangement; the complaint
that there are not enough babies for all the middle-class couples who desperately want to
adopt; the fate of orphaned frozen embryos whose wealthy progenitors died in an airplane
crash—all seem far removed from most Black people's lives. Yet it is precisely their racial
subtext that gives these images much of their emotional content. Ultimately, my attraction to
the Baby Jessica case, and cases like it, stems from my interest in the devaluation of Black
reproduction.” (emphasis omitted)); Roberts, supra note 90, at 938 (pointing out a news
story about reproduction that featured only pictures of white people having white babies).
98. Some websites scroll through different images or present different images each time
a viewer clicks on the website or refreshes it. For these websites, we recorded the race of the
babies that appeared the first time we went to the website or that automatically appeared
without any additional clicks. We did not refresh the website to see if other races appeared
because the race of the baby in those cases should be random, so recording an individual
instance should not skew the results.
99. This figure assumes that websites with pictures of babies of three or more races all
had pictures of white babies, which might be untrue but most likely is not based on the other
websites.
100. CIALDINI, supra note 26, at 140.
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of white babies give social proof to white individuals considering fertility care but
not to people who are of other races, driving up the number of white patients and
driving down the number of patients from other races.
The second narrative is more disturbing. It is possible that clinics are
purposefully using the race of babies to draw in white patients, confirming the
charge of some academics who argue that fertility treatments entrench racist
norms.101 Social psychologists have found that advertisements are effective if
people like the advertiser. People are most inclined to like people who are similar
to them:
We like people who are similar to us. This fact seems to hold true
whether the similarity is in the area of opinions, personality traits,
background or life-style. Consequently, those who wish to be liked in
order to increase our compliance can accomplish that purpose by
appearing similar to us in any of a wide variety of ways.102
Psychologists have also demonstrated that an association principle exists that
allows one person to lend positive traits to another person, product, or service.103 It
is possible that clinics are exploiting these advertising principles by using images
of white babies to create a halo effect for the clinic.
The second step I took to assess access to fertility care was to record how many
clinics advertised that they were multilingual since this advertisement may increase
access to non-English speakers and be a sign of welcome to minorities. Only
15.86% (n=59) of websites’ Home and About pages advertised that the clinics
offered services in multiple languages.
Finally, I counted the number of minority reproductive endocrinologists at
clinics. Scholarship in the past has noted anecdotal evidence about the dearth of
minority physicians, but it has also recognized that “empirical information [about
the race of physicians] does not seem to be available with respect to reproductive
endocrinologists.”104 We had no way to know with certainty the race of the
endocrinologists by viewing the websites, but we made assessments based on
pictures and last names. If we were unsure of the race, we did not code it. While
this method certainly resulted in some errors, they are likely the same errors that
other viewers of the webpages would make as well. We believed we could
determine the races of 1124 reproductive endocrinologists on clinics’ websites. Of

101. See Leslie Bender, Genes, Parents, and Assisted Reproductive Technologies: ARTs,
Mistakes, Sex, Race, & Law, 12 COLUM. J. GENDER & L. 1, 64 (2003) (noting the critique of
ART based on the fact the “use of these technologies reproduces the racist ideology in our
society that values white babies and their physical features over children of color and their
physical characteristics” and collecting sources making this claim).
102. CIALDINI, supra note 26, at 173.
103. Id. at 191 (“In one study, men who saw a new-car ad that included a seductive
young woman model rated the car as faster, more appealing, more expensive-looking, and
better designed than did men who viewed the same ad without the model.” (emphasis in
original) (citing George Horsley Smith & Rayme Engel, Influence of a Female Model on
Perceived Characteristics of an Automobile, 3 PROC. 76TH ANN. CONVENTION AM. PSYCHOL.
ASS’N 681 (1968))).
104. Elster, supra note 95, at 729.
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those physicians, 79.89% were white, 2.14% were black, 4.27% were Latino,
8.27% were Asian, and 5.43% were of other races. Table 6 presents the information
we recorded about their race.
Table 6: Races of Reproductive Endocrinologists Found on Clinics’ Websites
Race
Percentage
Number (out of 1124)
White
79.89
898
Black
2.14
24
Latino
4.27
48
Asian
8.27
93
Another Race Outside of
5.43
61
the Previous Categories
Like the images of babies, the percentage of black and Latino endocrinologists
is lower than the distribution of these races in the general population according to
the census, which is closer to 12.21% of the population being black or African
American and 16.35% being Latino.105
IV. THE INADEQUACY OF SELF-REGULATION TO POLICE FERTILITY CLINIC
MARKETING
The final goal of the study was to understand the efficacy of the industry’s
attempts at self-regulation. Studying how fertility clinics present advertising
information offers an opportunity to test theoretical claims about current selfregulation. Proponents and critics of self-regulation have offered a variety of
general arguments for and against this form of regulation—for instance, that selfregulation is efficient because it is created by experts in the industry or, in contrast,
that self-regulation is merely self-serving.106 These arguments are not important
merely because of their theoretical significance. Policymakers have held off on
regulating the fertility business in part because of self-regulation,107 so testing
whether it is sufficient in the context of clinic advertising should have practical
consequences for advertising policy and potentially other fertility policies.
Commentators have criticized the fertility industry’s self-regulation because
ASRM and SART have limited ability to police the industry. The only consequence
of failing to follow the guidelines is to lose membership in the organization. This

105. See KAREN R. HUMES, NICHOLAS A. JONES & ROBERTO R. RAMIREZ, OVERVIEW OF
RACE AND HISPANIC ORIGIN: 2010, at 4 (2011), available at http://www.census.gov/
prod/cen2010/briefs/c2010br-02.pdf. The census data does not correspond with how we
collected information because it separately asks what a person’s race is and whether the
person is of Hispanic origin. Id.
106. See Susan B. Apel, Access to Assisted Reproductive Technologies, 12 MICH. ST. J.
MED. & L. 33, 45–46 (2008) (summarizing the arguments on both sides); Angela J.
Campbell, Self-Regulation and the Media, 51 FED. COMM. L.J. 711, 715–17 (1999) (same).
107. Apel, supra note 106, at 37 (“[I]ndividual states have been slow to provide
legislation. Reasons for this may include the real or perceived difficulty in legislating in
areas where the relevant science is not easily understood, deference to physicians and the
recognition that the practice of medicine has been largely self-regulating . . . .”).
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consequence is extremely rare108 and possibly irrelevant to clinics that do not
believe membership is critical to continuing their businesses109 or that feel the
liberty to not comply.110 In contexts other than advertising, critics assert that
members of ASRM do not follow guidelines that set the number of embryos that
should be transferred111 or that prescribe how IVF refund programs should be
presented.112
In the context of websites, several studies have demonstrated low levels of
compliance with self-regulation. In 2005, Huang et al. conducted a study of fertility
clinics’ websites’ compliance with guidelines from the American Medical
Association about health information on the Internet.113 They found that
“[i]rrespective of the practice setting or university affiliation, the overall quality of
the fertility clinic websites is poor, failing to meet most of the AMA Internet health
information guidelines.”114 In 2007, Abusief et al. published a study of fertility
clinics’ compliance with the 2004 ASRM guidelines on advertising and concluded
that a “significant proportion of SART-member fertility clinics, both private and
academic, that have websites are not following the ASRM/SART guidelines for
advertising.”115

108. Id. at 41 (noting no clinics had been expelled as of the publication of the article in
2008). But see Radhika Rao, How (Not) to Regulate ARTs: Lessons from Octomom, 21 ALB.
L.J. SCI. & TECH. 313, 319 (2011) (noting ASRM expelled one doctor for implanting an
excessive number of embryos).
109. See Apel, supra note 106, at 41.
110. See also Velikonja, supra note 44, at 486 (2009) (“ASRM’s self-regulatory powers
are limited because its enforcement mechanisms are ineffective. Compliance with the
infertility guidelines is largely voluntary, and ASRM has no way of punishing noncompliant
clinics. . . . In addition, clinics do not have to be members of ASRM to offer infertility
services and are hence not even loosely bound by ASRM's embryo transfer guidelines.”). See
generally 138 CONG. REC. H5349 (daily ed. June 29, 1992) (statement of Rep. Ron Wyden)
(“The problem, however, is that any professional society can, at best, have a voluntary
program. We know that perhaps 15 percent of the clinics, those that probably cause the most
problems in terms of exploitation of families and the consumers, are the ones where couples
are not getting voluntary success-rate information, and where we are not seeing them follow
the sensible guidelines of the American Fertility Society. That is why it is time for
government to step in and set some basic ground rules to protect consumers and families in
this area.”); Kimberly D. Krawiec, Why We Should Ignore the “Octomom,” 104 NW. U. L.
REV. COLLOQUY 120, 121 (2009) (“Currently, decisions regarding the number of embryos to
transfer and, ultimately, fetuses to carry to term, are left to patients and their doctors.
Although the American Society for Reproductive Medicine (ASRM) and the Society for
Assisted Reproductive Technology (SART) have issued practice guidelines in an effort to
reduce the incidence of multiple births from ARTs, the guidelines are not mandatory and are
customizable according to the conditions of the individual patient.”).
111. See Rao, supra note 108, at 320 (citing evidence that fertility doctors admitted they
would not follow embryo transfer guidelines in a variety of contexts).
112. Hawkins, supra note 81, at 124–27.
113. Huang et al., supra note 13, at 541.
114. Id.
115. Abusief et al., supra note 43, at 88. More specifically, they found that:
Success rates were published on 51% of fertility clinic websites (117 private,
31 academic), the majority of which were private clinics (p=.025). The
percentage of fertility clinic websites adhering to ASRM/SART guidelines was
low in all categories (ranging from 2.8% to 54.5% in private centers and 1.3%
to 37.2% in academic centers). Fewer than half of all clinics publishing success
rates (35.5% of private clinics and 21.8% of academic clinics, p=.037) provided
information about the numerator and denominator used for calculation. Live-
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Yet, despite criticisms, doctors continue to insist on self-regulation,116 and
academic commentary offers support for self-regulation.117 Additionally, recent
research suggests that the level of compliance with Internet guidelines may be
increasing as the Internet becomes more prevalent in society and clinics respond to
past studies that pointed out noncompliance.118 Thus, this study is an important
continuing step in assessing the level of compliance with voluntary selfregulation.119
Some compliance with self-regulation can be assessed from data already
discussed in this Article. For instance, the American Medical Association has set
out what factors doctors should use to compete, including “quality of services, skill,
experience, miscellaneous conveniences offered to patients, credit terms, fees
charged, etc.”120 In a similar vein, SART requires that “[c]laims made in
advertising must be supported by verifiable published data.”121 Yet it is clear from
the noncommunicative information presented on and the other attributes
emphasized by clinic websites that many clinics are not complying with this
norm.122
birth data were reported on a minority of both private and academic clinics
(p=.468). The ASRM/SART guideline-mandated disclaimer statement, “A
comparison of success rates may not be meaningful because patient medical
characteristics and treatment approaches may vary from clinic to clinic,” was
present on only 65 clinic websites (43.9%) publishing success rates.
Id. at 90. A study of websites in Canada similarly found a high level of clinics not reporting
live birth rates. M.P. Vélez, G. Abad, J.M. Robert, F. Bissonnette & I.J. Kadoch, Quality
Assessment of Fertility Clinic Websites in Canada: A Comprehensive Approach, 26 HUMAN
REPROD. i337, i337 (2011) (finding “26 (63%) clinics listed pregnancy success rates, while
only 6 (15%) listed their live birth rates”).
116. There are many examples of doctors endorsing self-regulation, often in an attempt to
deter governmental intervention. See, e.g., Bryan D. Cowan, Veracity in in Vitro
Fertilization Web Pages, 83 FERTILITY & STERILITY 548, 548–49 (2005) (“[P]rofessional
organizations . . . should develop policies and procedures for Web-based information about
IVF and require all IVF Web sponsors to comply.”); Yakov M. Epstein & Helane S.
Rosenberg, Assessing Infertility Information on the Internet: Challenges and Possible
Solutions, 83 FERTILITY & STERILITY 553, 555 (2005) (“The time is ripe for the ASRM,
perhaps in partnership with consumer organizations such as RESOLVE, INCIID, and AFA,
to launch a task force to study the problem of managing fertility information on the Internet
and proposing useful solutions.”); Huang et al., supra note 13, at 543 (“More importantly,
professional organizations governing the practice of ART should develop more specific
guidelines . . . .”); Craig S. Niederberger, Assisted Reproductive Technologies on the Web,
83 FERTILITY & STERILITY 550 (2005) (“If we don’t heed Huang et al.’s clarion call to
improve SART-affiliated websites, we might find regulators knocking at our virtual doors, or
worse.”).
117. See Apel, supra note 106, at 49 (“Self-regulation within the medical profession is at
the moment the most viable means of controlling access issues, leaving less need for
legislation.”); cf. Naomi R. Cahn & Jennifer M. Collins, Eight Is Enough, 103 NW. U. L.
REV. COLLOQUY 501, 508 (2009) (observing that “most reproductive endocrinologists follow
[ASRM] standards”).
118. See Klitzman et al., supra note 25, at 1277 (noting that fertility clinics’ websites
have changed their content).
119. See Jain & Barbieri, supra note 16, at 547 (“With clearly defined advertising
parameters for fertility clinics set forth by the FTC and SART/ASRM, it would be of
concern if clinics are continuing to violate them.”).
120. COUNCIL ON ETHICAL AND JUDICIAL AFFAIRS, AM. MED. ASSOC., CODE OF MEDICAL
ETHICS OPINION 6.11 (1983).
121. SART Executive Council, supra note 49 (Policy #3).
122. See supra Part II.A.
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The more important type of self-regulation that my study can inform, however,
is the regulation of advertising that the SART Executive Council promulgated in
2009.123 These regulations require, among other guidelines that I did not test:
(1) “Advertising must comply with guidelines of the Federal Trade
Commission,”124 which require that clinics state the method for
calculating their success rates;125
(2) “[t]he following statement must be included when quoting program
statistics: ‘A comparison of clinic success rates may not be meaningful
because patient medical characteristics, treatment approaches and
entrance criteria for ART may vary from clinic to clinic.’”; 126
(3) “Because comparison of success rates between and among practices
is invalid, using SART or CDC Clinic Specific Data for
advertising/marketing that ranks or compares clinics or practices is
unacceptable and is not permitted. This prohibition includes
comparisons of outcomes of individual program(s) to any other
program whether named or anonymous.” 127
Based on my assessment of fertility clinics’ websites, I found a low level of
compliance with these guidelines. To test (1), compliance with the Federal Trade
Commission’s requirement that clinic describe how they reached their success
rates, we searched each clinic’s entire website to see if the website provided the
method used to calculate success rates (if success rates were mentioned on the
website). Of the 193 clinics that actually listed their success rates, 62.18% (n=120)
stated the method the clinic used for arriving at its success rate, and 37.82% (n=73)
failed to comply with this guideline.128
To assess compliance with (2), the required statement accompanying program
statistics, we noted instances where the websites’ Home and About pages used
program statistics and looked on those pages for the required statement Program
statistics were present on 15.09% (n=56) of the 372 Home and About pages we
viewed, and of those pages, 71.43% (n=40) had the required statement while
28.57% (n=16) did not.
The most complicated assessment was (3), the requirement that clinics not
compare the outcome of their programs with anything but national SARTgenerated averages. And this requirement is also very important because

123. SART Executive Council, supra note 49.
124. Id. (Policy #1).
125. Michael A. Katz, Federal Trade Commission Staff Concerns with Assisted
Reproductive Technology Advertising, 64 FERTILITY & STERILITY 10, 11 (1995) (explaining
that the commission’s “basic principles for advertising ART success rates” include the
requirement that “if a comparison is made to other clinics’ success rates or to a national
average, then the method of calculating the success rate must be the same”).
126. SART Executive Council, supra note 49 (Policy #5) (emphasis omitted).
127. Id. (Policy #4).
128. A reader might note that earlier I reported that 207 clinics used success rates to
market their clinic, but here only 193 clinics are presented. See supra Table 1. Because some
of the clinics that claim good success rates do not actually list their success rate, those clinics
were not included in the 193 we evaluated.
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comparisons strongly affect how we perceive reality,129 and comparisons between
the success rates at different clinics are very problematic.130 To assess compliance
with ASRM comparison guidelines, we recorded every time the Home or About
pages compared the clinic’s success rates to other groups. One hundred seventytwo clinics had comparison statements. I categorized the comparison statements of
those clinics into three groups: statements that compared the clinic to national
statistics, statements that compared the clinic to other groups of clinics beyond a
national average (such as clinics in a particular region or clinics worldwide), and
statements that used comparative language without specifying the entity to which
the clinic was being compared.
Of the clinics making comparison statements, 34.30% (n=59) followed the
ASRM guidelines and only made comparisons to national success rates.131 These
comparisons often followed along this line: “[W]e are proud to report success rates

129. See CIALDINI, supra note 26, at 11–12 (“There is a principle in human perception,
the contrast principle, that affects the way we see the difference between two things that are
presented one after another. Simply put, if the second item is fairly different from the first,
we will tend to see it as more different than it actually is.”).
130. Success rates can be reported using different numerators and different denominators.
For instance, the numerator, or the successes being counted, could either be chemical
pregnancies, clinical pregnancies (seven weeks gestation), ongoing pregnancies (gestation
past the second trimester), or live births. See Eggen, supra note 44, at 649–50; Success
Rates, BOCAFERTILITY, http://www.bocafertility.com/Success_Rates. These figures can be
compared against the number of cycles initiated, cycles that resulted in eggs being retrieved,
or cycles that resulted in an embryo being transferred as the denominator. Success Rates,
BOCAFERTILITY, http://www.bocafertility.com/Success_Rates. The choice of the numerator
and denominator yields radically different rates. As one clinic’s website explains, “an IVF
program can have relatively poor results with their medication protocols and/or fertilization
rates yet have high success rates per embryo transfer.” Id. Even when two clinics use the
same measure for the numerator and denominator, the success rates of the clinics are not
comparable because some clinics “will exclude potential IVF patients who are unlikely to
succeed, which will make them appear to have better success rates than those who accept
everyone who comes to them for help.” Id.; see also Abusief et al., supra note 43, at 92
(“Inconsistencies in the type of success rate published within or between fertility clinic
websites can potentially mislead patients about which rate applies to their situation.
Furthermore, analyses of success rates may require expertise not commonly held by patients
new to fertility treatment. Although some websites do include information about how to
interpret success rates, many other clinics do not differentiate [between different
situations].”); Goodwin, supra note 44, at 1727–32 (discussing problems associated with
defining “success” for success rates). These concerns echo legal principles involving
comparisons made by advertisers. See TUSHNET & GOLDMAN, supra note 23, at 306 (“With
some exceptions, courts have largely accepted the argument that comparisons should be
based on head-to-head testing, not on separate tests or studies. Different studies may select
differing populations, methodologies, endpoints and other factors that make comparison
difficult if not inherently misleading. . . . In addition, the ‘apples to apples’ principle requires
fairness in definition—though the advertiser is generally free to choose the terms of its
comparison, once those terms are chosen it must be consistent.”).
131. This finding tracks closely with a 2011 study of Canadian websites that found that
“[t]welve (29%) clinics stated that their success rates were higher than the national mean.”
Vélez et al., supra note 115, at 561.
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well above the national average, making us a leader in the field of infertility
treatment.”132
Another 19.19% (n=33) of clinics making comparison statements violated the
ASRM guidelines and compared the clinic’s success rates to other specific groups
of clinics, sometimes in addition to national averages. Some websites claimed the
clinic is the best in a region for success rates: “The Center’s good results have
produced one of the highest and most consistent overall success rates for all
infertility treatments in the region. The Center’s results for in-vitro-fertilization
(IVF) also are one of the highest and most consistent success rates in the region.”133
Other clinics make the comparison group broader than a national average, stating
“[w]e are proud that our IVF success rates are among the best in the world.”134 Still
others defined their comparison group as academic programs and costly private
programs135 or other leading fertility clinics.136
These statements appear to contradict the advertising guideline’s prohibition on
“comparisons of outcomes of individual program(s) to any other program whether
named or anonymous.”137 Each of these groups—regional, worldwide, and
university/costly programs—are anonymous programs to which the clinics are
offering comparisons. As the ASRM guidelines note, “comparison of success rates
between and among practices is invalid,”138 so these comparisons should not be
made on clinics’ websites under the guidelines.
Finally, 46.51% (n=80) of the websites making comparison statements did so
without specifying the exact clinic or group of clinics to which they were being
compared. Clinics’ websites claim that their success rates are superior,139
exceptional,140 incredibly high,141 among the best, 142 or unprecedented.143 These

132. Observation 9.
133. Observation 4. See also Observation 22 (“[W]e have a record of reliability, safety
and success with even the most difficult cases that is unmatched by any other regional
program.”); Observation 33 (“[The doctor] took over the former [clinic] in Orange County.
While [the former clinic] enjoyed some of the highest pregnancy rates in all of Southern
California, and certainly, Orange County, it wasn’t until [the doctor] successfully took over
sole control of the laboratory that the bar was raised yet again, with regards to IVF success
rates. . . . For the past 12 years, [the doctor] has had some of the highest IVF success rates in
Southern California.”); Observation 94 (claiming “some of the highest success rates in the
south Florida region”).
134. E.g., Observation 207.
135. E.g., Observation 243 (“We boast a level of success that is on par with sophisticated,
university-based programs and more costly patient-oriented private centers.”).
136. E.g., Observation 134 (noting the clinic’s success rates were not “unlike those from
other leading centers”).
137. SART Executive Council, supra note 49 (Policy #4).
138. Id.
139. Observation 44 (boasting “superior pregnancy rates”); Observation 21 (“While
upholding the highest standards of moral and ethical practices, we offer cutting edge and
state-of-the-art technologies to achieve superior pregnancy rates.”).
140. Observation 144 (“We are the only practice in central Indiana to offer IVF in an
office-based setting where comfort, safety, convenience, and exceptional pregnancy rates are
obtained.”).
141. Observation 31.
142. Observation 170.
143. Observation 157 (claiming “unprecedented success rates for assisted reproduction”).
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adjectives do not state a specific comparison, but each adjective only makes sense
if it is seen in light of a comparison group. A clinic alone cannot be exceptional or
superior, so these terms imply an anonymous comparison group, despite the
prohibition on making comparisons to such groups. It is possible that this final type
of comparison is insufficient to constitute a comparison because the competitor is
not identified, as at least one case from advertising law has concluded.144 But, I
think it is highly likely ASRM’s guidelines prohibit these generalized comparisons
because the guidelines specifically forbid comparisons with anonymous
competitors, so the guidelines, unlike the law, do not require that the competitor be
identified.
On balance, the level of compliance with the advertising self-regulation is
remarkably low. Regardless of the precise causes, clinics do not appear to feel
constrained by ASRM’s advertising guidelines. Contrary to the beliefs of
legislators restraining from regulating ART because of self-regulation, selfregulation alone does not appear to be an adequate policing mechanism to ensure
truthful advertising.
CONCLUSION
This Article offers the first global assessment of fertility clinic advertising that is
presented on clinics’ websites. It controverts some commonly held beliefs, such as
the belief in the supremacy of success rates as the only decision point for
consumers and the belief in academic clinics as path setters toward ethical conduct.
It also confirms several suspicions and theoretical positions taken in earlier
scholarship, such as the concern about access to ART by racial minorities and the
concern about the ability of the industry to police its own conduct. Whether
confronting or affirming prior convictions, this study has generated several
conclusions that suggest the need for regulators—both those inside the industry and
those outside it—to consider new regulations to ensure that the market functions
correctly and that clinics do not mislead consumers or capitalize on decisionmaking biases.
First, as a general matter, I hope the study encourages policymakers to take
greater interest in fertility clinic advertising. Because laws already address success
rates and because the industry actively engages in self-regulation, policymakers
may be lulled into a state of complaisance about the need for intervention to ensure
fertility markets function efficiently. By demonstrating that both of these beliefs are
highly questionable, I hope the study encourages policymakers to consider new
approaches to regulating fertility clinic advertising.

144. See TUSHNET & GOLDMAN, supra note 23, at 306 (“Yet not all advertising claiming
to provide ‘better’ or ‘stronger’ features is comparative. A competitor must be reasonably
identifiable. One court refused to find that an ad referring to ‘most spill proof cups,’ with a
picture of a cup that did not have any recognizable distinctiveness, compared the advertiser’s
product with the leading competitor. See Playtex Prods., Inc. v. Gerber Prods. Co., 981 F.
Supp. 827 (S.D.N.Y. 1997). Particularly in a field with many contenders, such as analgesics,
broad references to ‘better’ performance are unlikely to be deemed comparative without a
more specific identification of the comparator.”).
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More specifically, government regulators should consider requiring that clinics
present general pricing information about their services in a uniform manner to
enable patients to price shop between clinics.145 In other complicated financial
transactions, Congress has already required businesses to communicate pricing
information in a uniform manner. For example, the Truth in Lending Act requires
all lenders to present cost information about loans in the same way.146 If websites
listed prices in a uniform manner, patients would be able to assess at least that part
of the decision with minimal transaction costs. One objection to my suggestion is
that patients will just pick the fertility provider with the highest price because
customers generally use price as a proxy for quality147 and they especially are prone
to do so for medical services.148 However, given the evidence in the market of
clinics emphasizing low prices, it appears clinics do not think patients gravitate
towards high prices.
In addition, policymakers should consider whether the pervasive use of white
babies in current advertising needs to be counteracted by regulation requiring
clinics to incorporate babies of other races in their advertising. The Fair Housing
Act allows courts, for instance, to order rental businesses who have engaged in
discrimination to integrate different races into their advertising: “[F]ederal courts
and commentators have recognized, at least in the context of discriminatory rentals,
that affirmative action injunctions are not only appropriate, but necessary.”149
Commentary in that context has argued that affirmative requirements that
advertisers include racial minorities “can (1) change the process of all-white-model
real estate advertising by interrupting the exclusion of minority models and (2)
adjust for the effects of long-term discrimination by reaching out to previously
excluded readers.”150 In the same way, policymakers should consider whether
similar provisions should exist for fertility clinics that use babies in their
advertising.
Second, the industry should respond. Other practices that clinics are currently
engaging in are not well suited for governmental intervention. Members of the
industry, however, could take steps to eliminate them. For instance, clinics’ use of

145. Cf. Sage, supra note 50, at 1741 (suggesting standardization as one means of
mitigating problems communicating information to individual healthcare consumers).
146. 15 U.S.C. § 1601 (2012).
147. TUSHNET & GOLDMAN, supra note 23, at 30 (“These results are consistent with
earlier research finding that consumers often believe and judge lower priced items to be of
lower quality, even though objective testing (for example, done by Consumer Reports) often
finds no quality differences or advantages for the lower-priced versions.”).
148. Schneider & Hall, supra note 60, at 26 (“Even were the Internet widely used, how
consumerist would the results be? ‘Many have argued that patients using the Web to find
providers will finally bring price-sensitivity to health care consumption . . . . The exact
opposite is more likely to occur . . . . Not only will people never seek the lowest bidder when
it comes to their own physical and emotional well-being; they will actively seek out and
select the highest bidder, presuming (usually correctly) that higher cost connotes higher
quality . . . .’”) (quoting J.D. Kleinke, Vaporware.com: The Failed Promise of the Health
Care Internet, 19 HEALTH AFF.57, 67 (2000)).
149. Katherine G. Stearns, Countering Implicit Discrimination in Real Estate
Advertisements: A Call for the Issuance of Human Model Injunctions, 88 NW. U. L. REV.
1200, 1232 (1994).
150. Id. at 1234.
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the words “dream” and “miracle” and posting of baby pictures may mislead
consumers to associate treatment at the clinic with success. Lawmakers, however,
would have a difficult time intervening to stop this behavior because these terms
and practices are plainly puffery.151 ASRM, however, could specifically discourage
member clinics from using such tactics by prohibiting this behavior in its
advertising guidelines.
Also, ASRM could act in places where political pressure prevents policymakers
from acting. For example, ASRM could address access to ART by racial minorities.
ASRM could create concrete requirements for its member clinics to follow, such as
a requirement to use babies of multiple races if pictures of babies are present on a
website. The data on self-regulation suggest these attempts to self-regulate may fail
for some clinics, but given the political and practical problems of the government
acting, self-regulation could provide a second-best option.
Finally, academic clinics should consider whether they are fulfilling their
teaching mission in their advertising techniques. Because so many reproductive
endocrinologists interact with these clinics, they have an opportunity to encourage
ethical advertising that enhances competition within the fertility industry. Yet, the
study in this Article found that academic clinics are not at the forefront in ethical
advertising, suggesting a need for academic clinics to revise their practices.
As more of the population turns to the Internet to access information about
health, fertility clinic websites are likely to play an increasingly prominent role in
how patients pick their clinic. This Article has argued that regulators within and
outside the industry have missed some salient data points that consumers consider
when picking a clinic. More needs to be done to encourage truthful advertising and
to increase access to ART, and the government and the industry both have a role to
play in encouraging responsible practices.

151. See David A. Hoffman, The Best Puffery Article Ever, 91 IOWA L. REV. 1395, 1397
(2006) (explaining that, under the conventional view, puffery involves statements that are
too vague to evaluate and thus are immune from suit); TUSHNET & GOLDMAN, supra note 23,
at 168 (“Vague superlatives such as ‘best,’ ‘finest,’ ‘brightest,’ ‘most delicious,’ and the like
are so common that reasonable consumers are presumed to treat them as unverifiable,
unquantifiable, subjective, and unreliable.”).

